Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Agitated Delirium in Palliative Care: Does Haloperidol Need a Benzo-Boost?


Since new information is coming out about the safety of frequently used medications, pharmacists need to review this information with regard to previously published information and discuss how to apply the new information to the current patient population.
 
The safety and efficacy of benzodazepines for agitation in patients with delirium with advanced cancer will be examined.  Updated safety data and clinical evidence to support treatment modalities for agitated delirium in palliative care patients will be discussed.
 
This CE activity will be presented as an online Live activity.  All times listed are Central Time
 
Please click on this online Zoom link to join the activity: https://siue.zoom.us/j/884202801
 
 
 

Date: Dec 19, 2017 03:00 PM - 04:00 PM

Fee

$10.00

CE Hours

1.00

CE Units

0.100

Registration closes on Dec 19, 2017 02:45 PM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Disclosure Policy
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict.  The existence of relationships does not necessarily imply bias or lessen the value of the activity.  All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers.  The relevant commercial financial relationships or affiliations must have occured over the past 12 months.

 
Accreditation Council for Pharmacy Education
Southern Illinois University Edwardsville School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  
 
 
 
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of completing the activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity.   Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
 
 
 

 

Requirements for CE Credit

Participants have up to Friday January 5th to complete the online evaluation to receive credit for this activity

 

 

Registration closes on Dec 19, 2017 at 02:45 PM

Registration Closed  

Objectives

  • Describe the pharmacologic mechanisms of haloperidol and lorazepam for the treatment of agitated delirium
  • Discuss recent trial using haloperidol or risperidone for delirium in palliative care patients
  • Discuss background, methods, results, and clinical impact of the article presented

Speaker(s)/Author(s)

Christopher John Walczak picture

Christopher John Walczak, Pharm.D.
PGY2 Oncology Pharmacy Resident, OhioHealth Riverside Methodist Hospital


Brief Bio : Dr. Walczak is a PGY2 Resident at Riverside Memorial Hospital in Columbus Ohio. He completed his B.S. in Chemistry at Miami University (Ohio) and earned his Pharm.D. degree from The Ohio State University.

Activity Number

0480-0000-17-018-L01-P
Date: 12/19/17
Time: 03:00 PM - 04:00 PM

CE Hours

1.00

Fee

$10.00

Location

Internet: Zoom
Registration Closed